ADPT Adaptive Biotechnologies Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1478320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.9%
TTM net income YoY11.4%
TTM EPS YoY13.5%
Revenue 3-yr CAGR18.4%
Net income 3-yr CAGR—
Margins
Gross margin74.2%
Operating margin-16.2%
Net margin-23.7%
FCF margin-3.0%
EBITDA margin-11.6%
Returns
ROE-37.1%
ROA-12.0%
ROIC (approx.)-19.9%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets73.1%
Debt / equity0.00x
Current ratio3.97x
Interest coverage-5.33x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M |
| Cost of revenue | $71.36M | $72.08M | $75.55M | $57.91M | $49.30M |
| Gross profit | $205.62M | $106.88M | $94.72M | $127.40M | $105.04M |
| R&D expense | $93.77M | $102.95M | $122.12M | $141.76M | $142.34M |
| SG&A expense | $72.70M | $72.81M | $83.93M | $88.53M | $74.50M |
| Operating income | -$57.12M | -$162.55M | -$227.03M | -$200.19M | -$208.97M |
| Interest expense | $11.78M | $11.58M | $13.80M | $4.24M | — |
| Pretax income | -$59.46M | -$159.59M | -$225.30M | -$200.37M | -$207.30M |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$59.50M | -$159.49M | -$225.25M | -$200.19M | -$207.28M |
| EBITDA | -$41.12M | -$145.11M | -$207.44M | -$179.27M | -$196.71M |
| EPS (basic) | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 |
| EPS (diluted) | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 |
| Weighted avg. shares (diluted) | 151.72M | 147.10M | 144.38M | 142.52M | 140.35M |
| Balance sheet | |||||
| Cash & equivalents | $70.50M | $47.92M | $65.06M | $90.03M | $139.06M |
| Short-term investments | $156.49M | $174.37M | $281.34M | $408.17M | $214.00M |
| Receivables | $50.37M | $41.73M | $37.97M | $40.06M | $17.41M |
| Inventory | $9.82M | $8.44M | $14.45M | $14.45M | $19.26M |
| Current assets | $300.19M | $283.75M | $410.19M | $562.15M | $402.75M |
| PP&E, net | $34.11M | $48.62M | $68.23M | $83.45M | $85.26M |
| Goodwill | $118.97M | $118.97M | $118.97M | $118.97M | $118.97M |
| Intangibles | $1.73M | $3.42M | $5.13M | $6.83M | $8.53M |
| Total assets | $512.74M | $539.38M | $661.13M | $856.62M | $923.34M |
| Current liabilities | $89.92M | $98.05M | $88.02M | $109.79M | $113.81M |
| Short-term debt | $4.64M | $865,000 | — | — | — |
| Long-term debt | $126.57M | $132.41M | $130.66M | $125.36M | — |
| Total debt | $131.21M | $133.28M | $130.66M | $125.36M | — |
| Total liabilities | $287.74M | $336.89M | $352.86M | $392.52M | $319.24M |
| Shareholders' equity | $218.79M | $202.71M | $308.40M | $464.17M | $603.99M |
| Net debt | $60.71M | $85.36M | $65.60M | $35.33M | — |
| Shares outstanding | 153.78M | 147.77M | 145.08M | 143.11M | 141.39M |
| Cash flow statement | |||||
| Operating cash flow | -$45.99M | -$95.21M | -$156.32M | -$183.94M | -$192.73M |
| Capital expenditure | $2.96M | $3.66M | $10.70M | $16.35M | $61.75M |
| Free cash flow | -$48.95M | -$98.88M | -$167.02M | -$200.29M | -$254.47M |
| Investing cash flow | $37.95M | $77.79M | $129.65M | $2.90M | $181.21M |
| Financing cash flow | $30.40M | $241,000 | $2.25M | $132.26M | $27.15M |
| Depreciation & amortization | $16.00M | $17.44M | $19.60M | $20.92M | $12.25M |
| Stock-based compensation | $51.48M | $53.61M | $62.91M | $55.48M | $43.25M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.